Navigation Links
Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2009 Results
Date:3/15/2010

NANJING, March 16 /PRNewswire-Asia/ -- Simcere Pharmaceutical Group ("Simcere" or the "Company") (NYSE: SCR), a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today reported unaudited financial results for the quarter and the fiscal year ended December 31, 2009.

    Highlights

    -- Total revenue was RMB539.4 million (US$79.0 million) for the fourth
       quarter of 2009, compared to RMB466.9 million for the same period in
       2008, representing sequential growth of 15.5%. For the full year of
       2009, total revenue was RMB1,850.0 million (US$271.0 million), which
       represented an increase of 6.3% from RMB1,741.1 million for the full
       year of 2008.

    -- Gross margin for the fourth quarter of 2009 was 83.1%, compared to
       83.1% for the same period in 2008. For the full year of 2009, gross
       margin was 82.6%, increased from 81.6% for the full year of 2008.

    -- Income from operations was RMB44.9 million (US$6.6 million) for the
       fourth quarter of 2009, a decrease of 38.2% from RMB72.7 million for
       the same period in 2008. For the full year of 2009, income from
       operations was RMB172.9 million (US$25.3 million), which represented a
       decrease of 51.6% from RMB357.0 million for the full year of 2008.

    -- Net income attributable to Simcere was RMB17.7 million (US$2.6 million)
       for the fourth quarter of 2009, a decrease of 65.9% from RMB51.7
       million for the same period in 2008. For the full year of 2009, net
       income was RMB119.5 million (US$17.5 million), which represented a
       decrease of 65.9% from RMB350.2 million for the full year of 2008
'/>"/>
SOURCE Simcere Pharmaceutical Group
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Simcere Pharmaceutical Group Reports Unaudited Third Quarter 2009 Results
2. Simcere Pharmaceutical Group to Acquire China Manufacturing License for Rosuvastatin
3. Simcere Pharmaceutical Group Invested Company Obtains Production License for H1N1 Flu Vaccine
4. Simcere Announces Strategic Partnership with Sun Yat-Sen University Cancer Center
5. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2009 Results and Announces Share Repurchase
6. Simcere Pharmaceutical Group to Announce 2009 Second Quarter Earnings on Monday, August 17, 2009
7. Simcere Pharmaceutical Group Files Annual Report on Form 20-F
8. Simcere Pharmaceutical Group Seeking Approval to Manufacture and Sell Influenza Drug zanamivir
9. Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008
10. Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results
11. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... ... July 28, 2015 , ... ADLINK Technology, a ... edge devices that enable the Internet of Things (IoT), announced its new medical ... to provide exceptional computing power and multitasking capabilities. The MLC 4-21 is completely ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... much-anticipated U.S. commercial launch of its ORTHALIGN PLUS® system, a palm-sized, single-use navigation ... , “OrthAlign successfully combined precision with practicality in a revolutionary way for ...
(Date:7/28/2015)... ... July 28, 2015 , ... On July 16th NPR ... schedule the hearing of proposed bills and laws revolving the implementation of a small ... date. Some vigilante ministers are continuing to hand out clean needles to drug users ...
(Date:7/28/2015)... ... 2015 , ... BiologicsMD, Inc. , a privately held ... of bone disorders and conditions of hair loss, announced that the U.S. Patent ... Binding-Domain and Parathyroid Hormone". The issued patent claims methods of use for promoting ...
(Date:7/28/2015)... ... July 28, 2015 , ... Fertility specialist Dr. Lisa Hasty ... 2015” by Atlanta Magazine. In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty has ... colleagues and peers in the metro area as one of the most respected doctors ...
Breaking Medicine News(10 mins):Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 2Health News:ADLINK Launches High Performance, Fully-Sealed Medical-Grade Panel PC 3Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 2Health News:OrthAlign, Inc. Announces U.S. Commercial Launch of ORTHALIGN PLUS®, the most complete handheld navigation device for use in Total Hip Arthroplasty Surgery 3Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 2Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 3Health News:BiologicsMD, Inc. Announces Additional US Patent Issuance Covering Company’s Pipeline of Targeted Therapies 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3
... has revealed how change in body temperature impacts the ... Conti of the Scripps Research Institute in La Jolla, ... to prolong life and found that the lifespan of ... core body temperature, reported the health portal News Medical., ...
... meeting on breathing disorders in Paris discussed the ongoing research ... need to revamp the more than a century old test ... which the strains of TB have become resistant. ... the 37th world congress of the Union for breathing health ...
... restaurants to list the calories of all items offered in ... already offered the information regarding calories of various items offered by ... the back of tray liners and in restaurant brochures. ... are resisting the idea. It is a change to be welcomed ...
... Yoga is a path to optimal health by achieving a healthy ... undertaken by many for over 5,000 years//. ,The November ... and its health benefits. ,Yoga has its roots in ... of relaxation, postures and breathing. Several forms of yoga have evolved ...
... 100 health professionals put their heads together to thrash ... is weakening the healthcare system in Queensland. The// representatives ... nuclear medicine technologists in state-run hospitals has warned that ... staff, in the absence of any action. ...
... primary health care for patients that was released by ... developed// countries, except the U.S. ,In the ... it was found that Canada lagged in several aspects ... records, doctors availability after hours, multi-discipline teams for treatment ...
Cached Medicine News:
(Date:7/28/2015)... , July 20, 2015 ... addition of the "Global Post-traumatic Stress Disorder Therapeutics ... The global PTSD therapeutics market to grow at a ... This report covers the present scenario and the growth ... period 2015-2019. To calculate the market size, the report ...
(Date:7/28/2015)... July 28, 2015 According to a ... Type (Device, Formulation), Therapeutic (Hormonal, Oncology), Usage Pattern (Curative Care, ... - Forecast to 2020", published by MarketsandMarkets, the European Injectable ... 2020 from $114.7 Billion in 2015, growing at a CAGR ... 230 market data T ables ...
(Date:7/27/2015)... SEATTLE , July 28, 2015 CTI ... it plans to report its second quarter 2015 financial ... of the U.S. financial markets. Following the announcement, members ... call to discuss the results and provide a general ... Access to the event can be obtained as follows: ...
Breaking Medicine Technology:Global Post-traumatic Stress Disorder Therapeutics Market 2015-2019 - Growing Number of Accidents and Violence Worldwide Drives the Market 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 2European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 3European Injectable Drug Delivery Market Worth $207.3 Billion by 2020 4CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2
... Model of Diabetes with Haptoglobin 2-2 Genotype Show, ... Transport, MONTVALE, N.J., March 31 Synvista,Therapeutics, ... a study of diabetic mice,with the Haptoglobin 2-2 ... Haptoglobin (Hp)-Hemoglobin (Hb) complex may result in a ...
... is now enrolling ... patients, ... announced today the start of a Phase III clinical trial,studying LY450139, an ... LY450139 is being tested,to see if it can slow the progression associated ...
Cached Medicine Technology:Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 4Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 2Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 3Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 4Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 5Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease 6
... assays are designed for ... 2000, a high-throughput, continuous ... IMMULITE 2000 offers testing ... a rapidly expanding menu ...
... from KUBTEC is a dual capability system with ... representation of the specimen under test. While the ... images, the micro focus source also allows the ... standard 2D images. The 100 mm x 100 ...
... specimen radiography. The XPERT represents a research tool ... gray in every digital x-ray image, thus being ... that heretofore were lost to the human eye. ... 2 to 8 x 8 in size, multi-color ...
The Triage Profiler Shortness of Breath Panel provides rapid risk assessment and differential diagnosis of patients presenting to the emergency department with shortness of breath and risk assessment...
Medicine Products: